New agents in non-small cell lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000477:Alkylating Agents / Q000627:therapeutic use; D000818:Animals; D000880:Anthraquinones / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007191:Indazoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008942:Mitoxantrone; D014227:Triazines / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014751:Vindesine
D000477:Alkylating Agents; D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007191:Indazoles; D014227:Triazines; D014747:Vinblastine; D005047:Etoposide; D008942:Mitoxantrone; C012071:triazinate; D002945:Cisplatin; D014751:Vindesine; C016371:lonidamine; D007069:Ifosfamide